Kalhorn Ashton J, Tawse Kirstin L, Shah Avni A, Jung Jennifer L, Gregory Darren G, McCourt Emily A
University of Colorado School of Medicine, Aurora, CO.
Department of Ophthalmology, University of Colorado, Aurora, CO.
Cornea. 2018 Jul;37(7):912-915. doi: 10.1097/ICO.0000000000001512.
We report our experience with the use of maternally derived serum eye drops as adjunctive treatment in the management of pediatric persistent corneal epithelial defects.
Five eyes of 4 patients were identified in a retrospective review of pediatric patients with persistent corneal epithelial defects who received maternal serum drops. Diagnoses associated with the defects comprised pontine tegmental cap dysplasia with bilateral cranial nerve V1, V2, V3, and VII palsies; pontine tegmental cap dysplasia with left cranial nerve V1, VII, and VIII palsies; traumatic left cranial nerve II, V1, V2, and VI palsies due to a basilar skull fracture; and Stevens-Johnson syndrome with ocular involvement. We evaluated the feasibility of using maternally derived serum drops; thus, we looked at the ability to prepare and tolerate the drops as well as any complications that could have been associated with treatment. Other data collected included visual acuity, corneal examination, and current and previous treatments.
Both the duration of therapy and time of follow-up ranged from 5 to 28 months. All patients experienced improvement or resolution of their corneal epithelial defects within 3 weeks of initiating serum eye drops. Furthermore, there were no adverse effects from the use of allogeneic serum drops.
Maternal serum eye drops are a well-tolerated and potentially beneficial addition to the management of pediatric persistent corneal epithelial defects.
我们报告了使用母体血清滴眼液作为辅助治疗小儿持续性角膜上皮缺损的经验。
在一项对接受母体血清滴眼液治疗的小儿持续性角膜上皮缺损患者的回顾性研究中,确定了4例患者的5只眼。与缺损相关的诊断包括伴有双侧颅神经V1、V2、V3和VII麻痹的脑桥被盖部发育异常;伴有左侧颅神经V1、VII和VIII麻痹的脑桥被盖部发育异常;因颅底骨折导致的左侧外伤性颅神经II、V1、V2和VI麻痹;以及伴有眼部受累的史蒂文斯-约翰逊综合征。我们评估了使用母体血清滴眼液的可行性;因此,我们观察了制备和耐受滴眼液的能力以及可能与治疗相关的任何并发症。收集的其他数据包括视力、角膜检查以及当前和以前的治疗情况。
治疗持续时间和随访时间均为5至28个月。所有患者在开始使用血清滴眼液后3周内角膜上皮缺损均有改善或愈合。此外,使用异体血清滴眼液没有不良反应。
母体血清滴眼液耐受性良好,可能有助于小儿持续性角膜上皮缺损的治疗。